NOVEN
TO PRESENT AT DEUTSCHE BANK |
BackMiami, FL, April
25, 2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that Robert C. Strauss, its President, CEO & Chairman,
is scheduled to provide an update on Noven’s business and prospects
at the 32nd Annual Deutsche Bank Health Care Conference in Washington,
DC on Wednesday, May 2, 2007, at 9:00 a.m. Eastern Time. The public is
invited to listen to the presentation live via webcast at www.noven.com,
and a replay will be available for at least two weeks at the same site.
Noven
Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading
developer of advanced transdermal drug delivery technologies and prescription
transdermal products. Noven’s prescription patches are approved
in over 30 countries and include Vivelle-Dot® (the most prescribed
estrogen patch in the U.S.) and Daytrana™ (the first and only patch
approved for the treatment of ADHD). Noven is committed to expanding
the universe of available transdermal therapies for the benefit of patients,
partners and shareholders. See www.noven.com for additional information.
Contact: |
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.